Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies, a Prospective Randomized Controlled Trial

NCT03818334 is registered in ClinicalTrials.gov with Hospital Israelita Albert Einstein as lead sponsor.

NCT NCT03818334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03818334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies, a Prospective Randomized Controlled Trial
Lead sponsor
Hospital Israelita Albert Einstein
Phase
Phase 2/3
Overall status
Recruiting
Start date
November 6, 2018
Completion date
November 1, 2026
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone marrow transplant complications, engraft failure, graft versus host disease, immunologic suppression, infection viral